Tot Biopharm International Co Ltd

BioDlink International Company Limited is an investment holding company engaged in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. Its products include Pusintin, a bevacizumab injection for metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma multiforme, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer, as well as Tazian, a temozolomide capsule for glioblastoma and anaplastic astrocytoma. The company also develops TAB014, a bevacizumab ophthalmic drug for wet age-related macular degeneration (wAMD), and is involved in CDMO/CMO business, license-out of self-developed biological drugs, and business development, investing, and marketing promotion activities. Formerly known as TOT BIOPHARM International Company Limited, it changed its name to BioDlink International Company Limited in July 2025, was incorporated in 2009, is headquartered in Suzhou, China, and operates as a subsidiary of WuXi XDC Cayman Inc.